There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...
In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...
News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to their astronomical pricing, drug shortages, compounding disputes ...
Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
In this webinar, you’ll learn about GLP-1 agonists that can help with obesity treatment, common side effects of these drugs, misunderstandings about their use, and more. About the expert ...
Smoothie King says it is the first quick service restaurant brand with a GLP-1 focused menu.
In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...